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The preclinical development of chimeric antigen recep-
tor (CAR) T cell therapy has been hindered by the
inadequacy of current in vitro methods to predict T cell
performance (i.e. migration, proliferation and anti-tumor
activity), which do not recapitulate in vivo conditions.
For example, most T cell functional assays are per-
formed over a relatively short timeframe (6-18 hrs), and
platforms to assess T cell migration and prolonged
T cell-tumor cell interactions are very restricted. To
overcome these deficits, we developed the Go-CART –
an in vitro, compartmentalized culture system that
allows long-term assessment of multiple biological para-
meters simultaneously. The Go-CART is a six cham-
bered device (C1-C6) connected by 2mm channels that
form an “S” shaped, 11.5cm path, allowing the genera-
tion of a chemokine gradient (Figure 1). Thus, T cells
and tumor cells can be physically separated, allowing for
simultaneous in vitro assessment of T cell migration,
anti-tumor effects, and persistence. Furthermore, the
gas-permeable base of the Go-CART allows for pro-
longed T cell-tumor cell interaction (>2 weeks) without
medium/nutrient replenishment.
To explore whether we could establish a chemokine
gradient in the Go-CART, we added 24µg of MCP1 to
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compartment 1 (C1) and evaluated the chemokine levels
in all compartments. After 72 hours, we observed the for-
mation of a gradient that could drive T cell migration
(196.79, 78.52, 56.80, 9.79, 2.52 and 0.64ng/ml MCP1,
C1-C6, respectively). Next, to assess whether T cell migra-
tion could be induced by chemokine-producing tumor
cells, we established a 3D tumor model (AlgiMatrix seeded
with 1.00E+06 CAPAN1 tumor cells) in C1 and three days
later, added 2.00E+07 CAR-PSCA-FFluc-GFP T cells to
C6. We monitored T cell migration by periodic biolumi-
nescence imaging and after 5 days, observed an accumula-
tion of T cells at the tumor site (C1) (7.69E+06 and 3.19E
+08 p/s/cm2/sr, days 1 and 5, respectively). In contrast,
T cells failed to localize in the absence of tumor cells.
Finally, to assess the utility of the Go-CART in evaluating
anti-tumor effects, we established an AlgiMatrix-3D
tumor model in C1 with 1.00E+06 CAPAN1-FFLuc-GFP
tumor cells and three days later, added 2.00E+07
CAR-PSCA T cells to C6. Under these conditions, we
observed a progressive decrease in the tumor signal [3.52E
+08 (day 0) and 3.31E+07 (day 15) p/s/cm2/sr]. In
contrast, in the absence of T cells, the tumor signal
progressively increased [2.69E+08 (day 0) to 2.47E+09
(day 15) p/s/cm2/sr]. Thus, our results demonstrate that
the Go-CART can be used to dynamically assess multiple
parameters required for CAR T cell function.
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